Prulifloxacin

DB11892InvestigationalSmall molecule

Prulifloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a variety of susceptible bacterial infections. Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.

Formula / weight: C₂₁H₂₀FN₃O₆S · 461.46 g/mol (avg)

Resolves to

Compound

UNIIJ42298IESWCAS123447-62-1ChEMBLCHEMBL422648ChEBI32071PubChem65947

Clinical / RWD

ATCJ01MA17

Structure

InChIKeyPWNMXPDKBYZCOO-UHFFFAOYSA-NSMILESCC1SC2=C(C(O)=O)C(=O)C3=CC(F)=C(C=C3N12)N1CCN(CC2=C(C)OC(=O)O2)CC1

Targets

P10275AR P0A0K8gyrBP20831gyrAP0AFI2parC

Transporters

O15245SLC22A1

What you can answer from here — as of September 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

896Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

6ContraindicationsEach with its own population and attribute set

15Marketed productsAcross 3 countries and 6 labellers

1ATC codeIncluding every combination product, plus 19 drug categories

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prulifloxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account